Haleon has begun reformulating phenylephrine-containing oral decongestants marketed in the US as the company looks to get ahead of an anticipated FDA decision on the ingredient's use in OTC cough and cold products. The UK-based consumer health manufacturer revealed its plan as it reported organic sales up 3.5% in the first half of 2024.
Haleon is proactively reformulating Robitussin, Theraflu and Advil cough and cold products as the US Food and Drug Administration weighs up whether to pull approval for oral phenylephrine as a nasal decongestant.
CEO Brian McNamara told Haleon’s earnings call that the company had decided to act after a US FDA advisory committee...
Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
